Skip to main content

Advertisement

SpringerLink
Log in

Trial watch

Burgeoning oncology pipeline raises questions about sustainability

  • Biobusiness Briefs
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Therapeutic area focus of clinical-stage development programmes for new drugs.

Author information

Authors and Affiliations

  1. EvaluatePharma, London, UK

    Jon Moser & Paul Verdin

Authors
  1. Jon Moser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Verdin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jon Moser or Paul Verdin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

Indication (XLSX 191 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moser, J., Verdin, P. Burgeoning oncology pipeline raises questions about sustainability. Nat Rev Drug Discov 17, 698–699 (2018). https://doi.org/10.1038/nrd.2018.165

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.165

  • Springer Nature Limited

This article is cited by

Search

Navigation